Companies › ABL Bio
2 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Nov 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ABL103 Toll-like receptor 7/8 agonist | – | Phase 1 | Advanced Solid Tumor; Solid Tumors | Nov 2027 |
| ABL503 | – | Phase 1 | Advanced Solid Tumor | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04762641 | ABL503 | Phase 1 | Advanced Solid Tumor | Oncology | Nov 2025 |
| NCT06126666 | ABL103 | Phase 1 | Advanced Solid Tumor | Oncology | Nov 2027 |
| NCT07158918 | ABL103 | Phase 1 | Solid Tumors | Oncology | Dec 2027 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.